Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Research firm
Leerink Partners
Period: Reporting periods mapped to calendar 2024 Q3 – 2026 Q3 (9 quarters).
- Questions
- 243on tracked calls
- Challenge rate
- 9%21 of 243 questions
- Analysts
- 13with at least one question
- Companies
- 42questioned at least once
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Analysts
Most questions first. Each challenge rate shows the exact count behind it.
| Analyst | Companies | Questions | Challenge rate |
|---|---|---|---|
| Puneet Souda | 8 | 65 | 11%7 of 65 questions |
| Mike Cherny | 9 | 56 | 2%1 of 56 questions |
| Dave Risinger | 8 | 50 | 18%9 of 50 questions |
| Dan Clark | 5 | 20 | 10%2 of 20 questions |
| Whit Mayo | 4 | 15 | 0%none of 15 questions |
| Daina GrayboschLimited sample | 2 | 9 | 0%none of 9 questions |
| Mike KratkyLimited sample | 4 | 9 | 0%none of 9 questions |
| Joe SchwartzLimited sample | 1 | 8 | 25%2 of 8 questions |
| Andrew BerensLimited sample | 1 | 4 | 0%none of 4 questions |
| Marc GoodmanLimited sample | 1 | 3 | 0%none of 3 questions |
- Puneet Souda8 companies · 65 questions11%7 of 65 questions
- Mike Cherny9 companies · 56 questions2%1 of 56 questions
- Dave Risinger8 companies · 50 questions18%9 of 50 questions
- Dan Clark5 companies · 20 questions10%2 of 20 questions
- Whit Mayo4 companies · 15 questions0%none of 15 questions
- 0%none of 9 questions
- 0%none of 9 questions
- 25%2 of 8 questions
- 0%none of 4 questions
- 0%none of 3 questions
Show all 13 analysts
| Analyst | Companies | Questions | Challenge rate |
|---|---|---|---|
| Ben MayoLimited sample | 2 | 2 | 0%none of 2 questions |
| Unknown AnalystLimited sample | 1 | 1 | 0%none of 1 question |
| Mani ForooharLimited sample | 1 | 1 | 0%none of 1 question |
- 0%none of 2 questions
- 0%none of 1 question
- 0%none of 1 question
Companies
Most questions first, counting every analyst at this firm.
- TECHBio-Techne14 questions
- WATWaters Corporation14 questions
- AAgilent Technologies13 questions
- BMYBristol Myers Squibb10 questions
- IDXXIdexx Laboratories10 questions
- ALGNAlign Technology9 questions
- LHLabCorp9 questions
- RVTYRevvity9 questions
- CAHCardinal Health8 questions
- CORCencora8 questions
- INSMInsmed Incorporated8 questions
- VRTXVertex Pharmaceuticals8 questions
- MCKMcKesson Corporation7 questions
- DGXQuest Diagnostics7 questions
- HCAHCA Healthcare7 questions
- ABBVAbbVie7 questions
- PFEPfizer7 questions
- ILMNIllumina, Inc.6 questions
- LLYLilly (Eli)6 questions
- ZTSZoetis6 questions
- AMGNAmgen Inc.5 questions
- CVSCVS Health5 questions
- HUMHumana5 questions
- MRKMerck & Co., Inc.5 questions
Show all 42 companies
- REGNRegeneron Pharmaceuticals5 questions
- HSICHenry Schein4 questions
- IQVIQVIA4 questions
- GILDGilead Sciences4 questions
- DHRDanaher Corporation4 questions
- HOLXHologic4 questions
- INCYIncyte4 questions
- MDTMedtronic3 questions
- BIIBBiogen3 questions
- DXCMDexCom3 questions
- ELVElevance Health3 questions
- JNJJohnson & Johnson2 questions
- SYKStryker Corporation2 questions
- UNHUnitedHealth Group Incorporated1 question
- UHSUniversal Health Services1 question
- ALNYAlnylam Pharmaceuticals1 question
- PODDInsulet Corporation1 question
- TMOThermo Fisher Scientific1 question
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Analysts | Companies |
|---|---|---|---|---|
| 2024 Q3 | 5 | 0%none of 5 questions | 2 | 4 |
| 2024 Q4 | 45 | 2%1 of 45 questions | 11 | 33 |
| 2025 Q1 | 29 | 24%7 of 29 questions | 9 | 24 |
| 2025 Q2 | 35 | 9%3 of 35 questions | 7 | 28 |
| 2025 Q3 | 40 | 5%2 of 40 questions | 11 | 32 |
| 2025 Q4 | 28 | 7%2 of 28 questions | 7 | 22 |
| 2026 Q1 | 35 | 14%5 of 35 questions | 9 | 27 |
| 2026 Q2 | 24 | 4%1 of 24 questions | 8 | 22 |
| 2026 Q3 | 2 | 0%none of 2 questions | 2 | 2 |
- 2024 Q35 questions · challenge rate 0% (none of 5 questions) · 2 analysts · 4 companies
- 2024 Q445 questions · challenge rate 2% (1 of 45 questions) · 11 analysts · 33 companies
- 2025 Q129 questions · challenge rate 24% (7 of 29 questions) · 9 analysts · 24 companies
- 2025 Q235 questions · challenge rate 9% (3 of 35 questions) · 7 analysts · 28 companies
- 2025 Q340 questions · challenge rate 5% (2 of 40 questions) · 11 analysts · 32 companies
- 2025 Q428 questions · challenge rate 7% (2 of 28 questions) · 7 analysts · 22 companies
- 2026 Q135 questions · challenge rate 14% (5 of 35 questions) · 9 analysts · 27 companies
- 2026 Q224 questions · challenge rate 4% (1 of 24 questions) · 8 analysts · 22 companies
- 2026 Q32 questions · challenge rate 0% (none of 2 questions) · 2 analysts · 2 companies
Topics and sectors
Topics tagged on this firm’s questions
- Demand79
- Competitive Dynamics56
- Revenue Growth47
- Innovation & R&D46
- Product Launch35
- Regulation Policy35
- Guidance Reliability29
- Pricing28
- Macroeconomic19
- Margin16
Show all 21 topics
- Geographic Expansion14
- M&A12
- Capital Allocation10
- Trade Tariffs9
- Cost Pressure8
- Capex Investment5
- Cloud & AI5
- Supply Chain4
- Subscriber Growth2
- Credit1
- Inventory1
Questions by company sector
- Healthcare243